Last edition
News about "BCMA-directed bispecific antibody"
Pfizer Launches Elranatamab in India for Relapsed or Refractory Multiple Myeloma
Pfizer has launched Elranatamab in India for adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have received at least four prior therapies. The BCMA-directed bispecific antibody is available as a fixed-dose subcutaneous injection, offering a novel treatment option for heavily pretreated multiple myeloma patients.
BCMA-directed Bispecific Antibody | 03/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy